Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 5

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 5
---
 Product Sales and Collaboration Revenue consists of EPKINLY Net Product Sales in the U.S. and Japan and Tivdak (Genmab’s share of net profits) in the U.S. and Net Product Sales in Japan

** Operating Expenses Range excludes Cost of Product Sales Range, which is included in Gross Profit Range

Genmab is updating its revenue and operating profit guidance for 2025. The improved guidance is driven by higher total royalty revenues from DARZALEX.

Revenue Genmab expects its 2025 revenue to be in the range of $3.5 - 3.7 billion, an increase to the previous guidance range of $3.3 - 3.7 billion. Genmab’s projected revenue growth for 2025 is driven by higher royalties, net product sales and collaboration revenue.

Royalty growth relates mainly to DARZALEX and Kesimpta net sales growth. DARZALEX royalties of $2.3 - $2.4 billion are based on Genmab’s estimate of DARZALEX 2025 net sales of $13.7 – 14.1 billion. DARZALEX royalties are partly offset by Genmab’s share of Janssen’s royalty payments to Halozyme Therapeutics, Inc. (Halozyme) in connection with SC net sales as well as royalty reduction in countries and territories where there are no Genmab patents.

Operating Expenses Genmab is maintaining its 2025 operating expenses to be in the range of $2.1 - 2.2 billion.

Operating Profit Genmab expects its 2025 operating profit to be in the range of $1.1 - 1.4 billion, compared to previous guidance range of $0.9 - 1.4 billion, primarily driven by the items described above.

Outlook: Risks and Assumptions In addition to factors already mentioned, the estimates above are subject to change due to numerous reasons, including but not limited to, the achievement of certain milestones associated with Genmab’s collaboration agreements; the timing and variation of development activities (including activities carried out by Genmab’s collaboration partners) and related income and costs; DARZALEX, DARZALEX FASPRO , Kesimpta, TEPEZZA, RYBREVANT, TECVAYLI, TALVEY and TEPKINLY net sales and royalties paid to Genmab; changing rates of inflation; and currency exchange